triazoles has been researched along with Spondylitis, Ankylosing in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baraliakos, X; Barchuk, W; Besuyen, R; Gilles, L; Hendrikx, T; Landewé, R; Liu, K; Maksymowych, WP; Østergaard, M | 1 |
| Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L | 1 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Adas, M; Bechman, K; Cope, AP; Galloway, JB; Mootoo, A; Norton, S; Patel, V; Qureshi, S; Rampes, S; Yates, M | 1 |
| Coates, LC; White, JPE | 1 |
| Baraliakos, X; Barchuk, W; Besuyen, R; Gilles, L; Hendrikx, T; Landewé, R; Liu, K; Maksymowych, WP; Tasset, C; Østergaard, M | 1 |
| McInnes, IB; Siebert, S | 1 |
| Abi-Saab, W; Baraliakos, X; Besuyen, R; Deodhar, A; Gensler, LS; Greer, JM; Hendrikx, T; Landewé, R; Liu, K; Maksymowych, WP; Meuleners, L; Mozaffarian, N; Nadashkevich, O; Tasset, C; Tseluyko, V; van der Heijde, D | 1 |
| Collison, J | 1 |
| Al-Mossawi, MH; Bowness, P; Brennan, PE; de Wit, J; Fedorov, O; Hammitzsch, A; Hay, DA; Knapp, S; Martinez, FO; Müller, S; O'Mahony, A; Tallant, C; Vecellio, M; Wells, C; Wordsworth, P | 1 |
4 review(s) available for triazoles and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles | 2020 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pulmonary Embolism; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles; Venous Thromboembolism; Venous Thrombosis | 2021 |
JAK1 selective inhibitors for the treatment of spondyloarthropathies.
Topics: Arthritis, Psoriatic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Spondylarthropathies; Spondylitis, Ankylosing; Triazoles | 2021 |
2 trial(s) available for triazoles and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Topics: Adult; Humans; Janus Kinase Inhibitors; Magnetic Resonance Imaging; Metaplasia; Pyridines; Sacroiliac Joint; Spondylarthritis; Spondylitis, Ankylosing; Triazoles | 2022 |
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Topics: Adult; Antirheumatic Agents; Double-Blind Method; Female; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Middle Aged; Nasopharyngitis; Opportunistic Infections; Pneumonia; Pyridines; Severity of Illness Index; Spondylitis, Ankylosing; Treatment Outcome; Triazoles | 2018 |
4 other study(ies) available for triazoles and Spondylitis, Ankylosing
| Article | Year |
|---|---|
Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.
Topics: Humans; Inflammation; Magnetic Resonance Imaging; Pyridines; Severity of Illness Index; Spine; Spondylarthritis; Spondylitis, Ankylosing; Triazoles; Vertebral Body; Zygapophyseal Joint | 2022 |
The extending scope of kinase inhibition in immune diseases.
Topics: Humans; Immune System Diseases; Janus Kinase 1; Protein Kinase Inhibitors; Pyridines; Spondylitis, Ankylosing; Triazoles | 2018 |
Selective JAK inhibition for AS.
Topics: Humans; Janus Kinase 1; Protein Kinase Inhibitors; Pyridines; Spondylitis, Ankylosing; Triazoles | 2018 |
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Topics: Adult; Aged; Arthritis, Psoriatic; Azepines; Benzimidazoles; Calorimetry; CD4-Positive T-Lymphocytes; Cells, Cultured; Crystallography, X-Ray; Drug Evaluation, Preclinical; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-17; Isoxazoles; Kinetics; Male; Middle Aged; Models, Molecular; Molecular Structure; p300-CBP Transcription Factors; Protein Conformation; Protein Structure, Tertiary; Recombinant Proteins; Spondylitis, Ankylosing; Structure-Activity Relationship; Th17 Cells; Triazoles | 2015 |